RESUMO
BACKGROUND: Surgical site infections (SSIs) are associated with morbidity, mortality and costs. AIM: To identify the burden of (deep) SSIs in costs and disability-adjusted life years (DALYs) following colectomy, mastectomy and total hip arthroplasty (THA) in the Netherlands. METHODS: A retrospective cost-analysis was performed using 2011 data from the national SSI surveillance network PREZIES. Sixty-two patients with an SSI (exposed) were matched to 122 patients without an SSI (unexposed, same type of surgery). Patient records were studied until 1 year after SSI diagnosis. Unexposed patients were followed for the same duration. Costs were calculated from the hospital perspective (2016 price level), and cost differences were tested using linear regression analyses. Disease burden was estimated using the Burden of Communicable Disease in Europe Toolkit of the European Centre for Disease Prevention and Control. The SSI model was specified by type of surgery, with country- and surgery-specific parameters where possible. FINDINGS: Attributable costs per SSI were 21,569 (THA), 14,084 (colectomy) and 1881 (mastectomy), mainly caused by prolonged length of hospital stay. National hospital costs were estimated at 10 million, 29 million and 0.6 million, respectively. National disease burden was greatest for SSIs following colectomy (3200 DALYs/year, 150 DALYs/100 SSIs), while individual disease burden was highest following THA (1200 DALYs/year, 250 DALYs/100 SSIs). For mastectomy, these DALYs were <1. The total cost of DALYs for the three types of surgery exceeded 88 million. CONCLUSION: Depending on the type of surgery, SSIs cause a significant burden, both economically and in loss of years in full health. This underlines the importance of appropriate infection prevention and control measures.
Assuntos
Efeitos Psicossociais da Doença , Infecção da Ferida Cirúrgica/epidemiologia , Idoso , Idoso de 80 Anos ou mais , Artroplastia de Quadril/efeitos adversos , Colectomia/efeitos adversos , Feminino , Custos de Cuidados de Saúde , Humanos , Masculino , Mastectomia/efeitos adversos , Pessoa de Meia-Idade , Países Baixos/epidemiologia , Estudos Retrospectivos , Análise de SobrevidaAssuntos
Controle de Doenças Transmissíveis/economia , Controle de Doenças Transmissíveis/métodos , Análise Custo-Benefício/métodos , Transmissão de Doença Infecciosa/prevenção & controle , Influenza Humana/epidemiologia , Influenza Humana/prevenção & controle , Humanos , Influenza Humana/economia , Modelos EstatísticosRESUMO
A recent survey has shown that the EEG is of doubtful value as an outcome variable in clinical antiepileptic drug (AED) trials. Analysis of findings in 6 trials shows that in only two no consistent effect was seen; that in two power spectral analysis provided additional information to confirm changes in background activity; that in one a close relationship could be established between reduction in frequency of epileptiform discharges and administration of the trial drug (lamotrigine), and that in one, even though no correlation was apparent during use of the AED, there was an increase in frequency of both discharges and seizures on withdrawal (CGP 11952). In general the EEG would appear to be unsuitable as an outcome variable for assessing drug efficacy in AED trials. On the other hand it may give insight into the mode of drug action. Conceivably more efficient use could be made of the EEG if the methodology--including patient selection, consideration of circadian rhythms and of combination AED therapy, and standardized long-term recording--were to be improved and automation and quantification techniques used.
Assuntos
Anticonvulsivantes/uso terapêutico , Encéfalo/fisiopatologia , Epilepsia/tratamento farmacológico , Adolescente , Adulto , Encéfalo/efeitos dos fármacos , Ensaios Clínicos como Assunto , Método Duplo-Cego , Eletroencefalografia , Epilepsia/fisiopatologia , Feminino , Humanos , Masculino , Pessoa de Meia-IdadeRESUMO
A requirement for intensive epilepsy monitoring arose from a demand for ictal EEG registration for diagnostic purposes and in the context of pharmacokinetic research. The monitoring facility developed gradually: first conventional EEG equipment was used on the wards, later miniaturized pre-amplifiers were introduced to allow the patient greater freedom, finally a comprehensive specialized monitoring facility was created with its own accommodation. For most clinical and research applications arising in the Institute intensive observation and video monitoring are necessary. The greater reliability, channel capacity and bandwidth of cable telemetry offer considerable advantages over alternative monitoring techniques as radio telemetry. For recording from patients in locations outside the monitoring unit but where restricted mobility is acceptable a combination of telephone telemetry with a local radio link is used. Synchronization of EEG and video images is achieved by various means, depending on the application: split-screen technique, superimposition of EEG on video images or annotating the paper EEG chart with digital time information derived from the video time-date generator. Buffering of EEG signals is also available by means of a computer disk or a shift register. During the development of the system evaluation studies have been performed showing a progressively increasing yield of clinically useful information. At the most recent assessment, 79% of the investigations answered the clinical question addressed, in 65% of instances the findings had consequences for management and in over 25% the decisions resulting from monitoring had long-term therapeutic benefits for the patient.